|
WO2012019168A2
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP2625189B1
(en)
|
2010-10-01 |
2018-06-27 |
ModernaTX, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
AU2012236099A1
(en)
|
2011-03-31 |
2013-10-03 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
WO2013032829A1
(en)
*
|
2011-08-26 |
2013-03-07 |
Arrowhead Research Corporation |
Poly(vinyl ester) polymers for in vivo nucleic acid delivery
|
|
WO2013033230A1
(en)
|
2011-08-29 |
2013-03-07 |
Isis Pharmaceuticals, Inc. |
Oligomer-conjugate complexes and their use
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
DE19216461T1
(de)
|
2011-10-03 |
2021-10-07 |
Modernatx, Inc. |
Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
|
|
CA3018046A1
(en)
|
2011-12-16 |
2013-06-20 |
Moderna Therapeutics, Inc. |
Modified nucleoside, nucleotide, and nucleic acid compositions
|
|
US8796405B2
(en)
*
|
2012-01-18 |
2014-08-05 |
Wisconsin Alumni Research Foundation |
Degradable polycations derived from amino acid vinyl esters
|
|
WO2013151665A2
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of proteins associated with human disease
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
CA2842041A1
(en)
*
|
2012-04-18 |
2013-10-24 |
Arrowhead Research Corporation |
Poly(acrylate) polymers for in vivo nucleic acid delivery
|
|
PL2922554T3
(pl)
|
2012-11-26 |
2022-06-20 |
Modernatx, Inc. |
Na zmodyfikowany na końcach
|
|
CN105247051A
(zh)
|
2013-02-28 |
2016-01-13 |
箭头研究公司 |
治疗epas1相关疾病的有机组合物
|
|
EP3494966B1
(en)
*
|
2013-03-13 |
2024-04-03 |
onCOUR Pharma, Inc. |
Immune-modifying particles for the treatment of inflammation
|
|
WO2014152211A1
(en)
|
2013-03-14 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
DK2992098T3
(da)
|
2013-05-01 |
2019-06-17 |
Ionis Pharmaceuticals Inc |
Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression
|
|
WO2015021092A1
(en)
|
2013-08-07 |
2015-02-12 |
Arrowhead Research Corporation |
Polyconjugates for delivery of rnai triggers to tumor cells in vivo
|
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
EP3041934A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
EP3052521A1
(en)
|
2013-10-03 |
2016-08-10 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
|
WO2015168172A1
(en)
|
2014-04-28 |
2015-11-05 |
Isis Pharmaceuticals, Inc. |
Linkage modified oligomeric compounds
|
|
US9382540B2
(en)
|
2014-05-01 |
2016-07-05 |
Isis Pharmaceuticals, Inc |
Compositions and methods for modulating angiopoietin-like 3 expression
|
|
EA036496B1
(ru)
|
2014-05-01 |
2020-11-17 |
Ионис Фармасьютикалз, Инк. |
Конъюгированные олигонуклеотиды для модулирования экспрессии фактора комплемента b
|
|
HUE052709T2
(hu)
|
2014-05-01 |
2021-05-28 |
Ionis Pharmaceuticals Inc |
Módosított antiszensz oligonukleotidok konjugátumai és azok alkalmazása PKK expressziójának módosítására
|
|
BR112016022742B1
(pt)
|
2014-05-01 |
2022-06-14 |
Ionis Pharmaceuticals, Inc |
Composto químico, composição compreendendo o composto e uso dos mesmos
|
|
WO2015179693A1
(en)
|
2014-05-22 |
2015-11-26 |
Isis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
|
TW201620526A
(zh)
|
2014-06-17 |
2016-06-16 |
愛羅海德研究公司 |
用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
|
|
US20170204152A1
(en)
|
2014-07-16 |
2017-07-20 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
EP3171895A1
(en)
|
2014-07-23 |
2017-05-31 |
Modernatx, Inc. |
Modified polynucleotides for the production of intrabodies
|
|
US10436802B2
(en)
|
2014-09-12 |
2019-10-08 |
Biogen Ma Inc. |
Methods for treating spinal muscular atrophy
|
|
AR104754A1
(es)
|
2015-05-29 |
2017-08-09 |
Arrowhead Pharmaceuticals Inc |
Agentes de unión de tetrapéptido escindibles biológicamente
|
|
MX2018000412A
(es)
|
2015-07-10 |
2018-03-14 |
Ionis Pharmaceuticals Inc |
Moduladores de diaciglicerol aciltransferasa 2 (dgat2).
|
|
AU2016306275A1
(en)
|
2015-08-07 |
2018-02-08 |
Arrowhead Pharmaceuticals, Inc. |
RNAi therapy for Hepatitis B virus infection
|
|
CN108513588A
(zh)
|
2015-09-24 |
2018-09-07 |
Ionis制药公司 |
Kras表达的调节剂
|
|
JOP20160211B1
(ar)
|
2015-10-01 |
2021-08-17 |
Arrowhead Pharmaceuticals Inc |
تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
|
|
EP4011451A1
(en)
|
2015-10-22 |
2022-06-15 |
ModernaTX, Inc. |
Metapneumovirus mrna vaccines
|
|
WO2017070601A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Nucleic acid vaccines for varicella zoster virus (vzv)
|
|
JP7384512B2
(ja)
|
2015-10-22 |
2023-11-21 |
モデルナティエックス インコーポレイテッド |
広域インフルエンザウイルスワクチン
|
|
EP3365009A4
(en)
|
2015-10-22 |
2019-07-03 |
ModernaTX, Inc. |
VACCINES AGAINST HERPES SIMPLEX VIRUS
|
|
AU2016342045A1
(en)
|
2015-10-22 |
2018-06-07 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
EA201891000A1
(ru)
|
2015-10-22 |
2018-12-28 |
МОДЕРНАТиЭкс, ИНК. |
Вакцина против респираторно-синцитиального вируса
|
|
PL4119569T3
(pl)
|
2015-11-06 |
2024-11-18 |
Ionis Pharmaceuticals, Inc. |
Sprzężone związki antysensowne do zastosowania w terapii
|
|
KR20250078597A
(ko)
|
2015-11-06 |
2025-06-02 |
아이오니스 파마수티컬즈, 인코포레이티드 |
아포리포프로테인 (a) 발현 조정
|
|
PL3394093T3
(pl)
|
2015-12-23 |
2022-05-16 |
Modernatx, Inc. |
Metody stosowania polinukleotydów kodujących ligand ox40
|
|
MA43587A
(fr)
|
2016-01-10 |
2018-11-14 |
Modernatx Inc |
Arnm thérapeutiques codant pour des anticorps anti-ctla-4
|
|
CA3011946A1
(en)
|
2016-03-07 |
2017-09-14 |
Arrowhead Pharmaceuticals, Inc. |
Targeting ligands for therapeutic compounds
|
|
MX2018015109A
(es)
|
2016-06-06 |
2019-04-22 |
Arrowhead Pharmaceuticals Inc |
Nucleotidos modificados con 5'-ciclo-fosfonato.
|
|
EP3484524B1
(en)
|
2016-07-15 |
2022-11-09 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of smn2
|
|
JOP20190015A1
(ar)
|
2016-08-04 |
2019-02-04 |
Arrowhead Pharmaceuticals Inc |
عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
|
|
SG11201901841TA
(en)
|
2016-09-02 |
2019-03-28 |
Arrowhead Pharmaceuticals Inc |
Targeting ligands
|
|
US11400161B2
(en)
|
2016-10-06 |
2022-08-02 |
Ionis Pharmaceuticals, Inc. |
Method of conjugating oligomeric compounds
|
|
CN110268060B
(zh)
|
2017-01-10 |
2024-07-26 |
箭头药业股份有限公司 |
α-1抗胰蛋白酶(AAT)RNAi物质、包含AAT RNAi物质的组合物和使用方法
|
|
AU2018213379A1
(en)
|
2017-01-30 |
2019-07-18 |
Arrowhead Pharmaceuticals Inc. |
Compositions and methods for inhibition of factor XII gene expression
|
|
JOP20190215A1
(ar)
|
2017-03-24 |
2019-09-19 |
Ionis Pharmaceuticals Inc |
مُعدّلات التعبير الوراثي عن pcsk9
|
|
MA49421A
(fr)
|
2017-06-15 |
2020-04-22 |
Modernatx Inc |
Formulations d'arn
|
|
TN2019000308A1
(en)
|
2017-07-06 |
2021-05-07 |
Arrowhead Pharmaceuticals Inc |
RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE
|
|
EP3675817A1
(en)
|
2017-08-31 |
2020-07-08 |
Modernatx, Inc. |
Methods of making lipid nanoparticles
|
|
KR20240161202A
(ko)
|
2017-09-11 |
2024-11-12 |
애로우헤드 파마슈티컬스 인코포레이티드 |
아포지단백질 C-III (APOC3)의 발현을 억제하기 위한 RNAi 작용제 및 조성물
|
|
TN2020000038A1
(en)
|
2017-09-14 |
2021-10-04 |
Arrowhead Pharmaceuticals Inc |
Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use
|
|
JP7473472B2
(ja)
|
2017-10-17 |
2024-04-23 |
アローヘッド ファーマシューティカルズ インコーポレイテッド |
アシアロ糖タンパク質受容体１の発現を阻害するためのＲＮＡｉ剤および組成物
|
|
AU2019206731A1
(en)
|
2018-01-15 |
2020-07-30 |
Ionis Pharmaceuticals, Inc. |
Modulators of DNM2 expression
|
|
WO2019157531A1
(en)
|
2018-02-12 |
2019-08-15 |
Ionis Pharmaceuticals, Inc. |
Modified compounds and uses thereof
|
|
CU20200082A7
(es)
|
2018-05-09 |
2021-06-08 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para la reducción de la expresión de fxi
|
|
US12496311B2
(en)
|
2018-07-17 |
2025-12-16 |
Aronora, Inc. |
Methods for safely reducing thrombopoietin
|
|
EP3833397A4
(en)
|
2018-08-08 |
2023-06-14 |
Arcturus Therapeutics, Inc. |
COMPOSITIONS AND AGENTS AGAINST NON-ALCOHOLIC STEATOHEPATITIS
|
|
KR102769565B1
(ko)
|
2018-09-19 |
2025-02-20 |
애로우헤드 파마슈티컬스 인코포레이티드 |
17베타-HSD 유형 13- (HSD17B13)의 발현을 억제하기 위한 RNAi 작용제, 그의 조성물, 및 사용 방법
|
|
TW202542311A
(zh)
|
2018-09-19 |
2025-11-01 |
美商Ionis製藥公司 |
Pnpla3表現之調節劑
|
|
WO2020061457A1
(en)
|
2018-09-20 |
2020-03-26 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
CR20210395A
(es)
|
2018-12-21 |
2021-11-05 |
Ionis Pharmaceuticals Inc |
Moduladores de la expresión de hsd17b13
|
|
SG11202105577TA
(en)
|
2019-01-09 |
2021-06-29 |
Arrowhead Pharmaceuticals Inc |
Rnai agents for inhibiting expression of hif-2 alpha (epas1), compositions thereof, and methods of use
|
|
WO2020163747A1
(en)
|
2019-02-07 |
2020-08-13 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for hepatitis b virus infection
|
|
MX2021015003A
(es)
|
2019-06-06 |
2022-01-24 |
Arrowhead Pharmaceuticals Inc |
Metodos para el tratamiento de la deficiencia de alfa-1 antitripsina (aatd).
|
|
KR20220042116A
(ko)
|
2019-06-18 |
2022-04-04 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
B형 간염 바이러스(HBV) 백신 및 HBV-타케팅 RNAi의 조합
|
|
CA3143679A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai
|
|
WO2021074772A1
(en)
|
2019-10-14 |
2021-04-22 |
Astrazeneca Ab |
Modulators of pnpla3 expression
|
|
CN120505310A
(zh)
|
2020-02-28 |
2025-08-19 |
Ionis制药公司 |
用于调节smn2的化合物和方法
|
|
AR121672A1
(es)
|
2020-03-26 |
2022-06-29 |
Arrowhead Pharmaceuticals Inc |
AGENTES DE ARNi PARA INHIBIR LA EXPRESIÓN DE PNPLA3, COMPOSICIONES FARMACÉUTICAS DE ESTA, Y MÉTODOS DE USO
|
|
CN115916262A
(zh)
|
2020-04-21 |
2023-04-04 |
旗舰创业股份有限公司 |
双官能分子及其使用方法
|
|
CN116348150A
(zh)
|
2020-09-11 |
2023-06-27 |
箭头药业股份有限公司 |
用于递送治疗剂的脂质缀合物
|
|
MX2023002939A
(es)
|
2020-09-11 |
2023-04-11 |
Arrowhead Pharmaceuticals Inc |
Plataformas para el transporte de farmacos hacia el musculo esqueletico y metodos de uso.
|
|
CA3189065A1
(en)
|
2020-09-11 |
2022-03-17 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of dux4, compositions thereof, and methods of use
|
|
LT4136092T
(lt)
|
2020-11-18 |
2024-09-25 |
Ionis Pharmaceuticals, Inc. |
Junginiai ir būdai, skirti angiotenzinogeno raiškos moduliavimui
|
|
JP2024516096A
(ja)
|
2021-04-08 |
2024-04-12 |
アローヘッド ファーマシューティカルズ インコーポレイテッド |
終末糖化産物受容体の発現を阻害するためのＲＮＡｉ剤、その組成物、及び使用方法
|
|
TW202304472A
(zh)
|
2021-04-23 |
2023-02-01 |
美商格納生物公司 |
經聚醣修飾之核酸、製備方法及治療用途
|
|
MX2023014026A
(es)
|
2021-05-28 |
2023-12-12 |
Arrowhead Pharmaceuticals Inc |
Agentes de rnai para inhibir la expresion de mucina 5ac (muc5ac), composiciones de estos y metodos de uso.
|
|
US11629349B2
(en)
|
2021-06-21 |
2023-04-18 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use
|
|
US12042509B2
(en)
|
2021-10-01 |
2024-07-23 |
Adarx Pharmaceuticals, Inc. |
Prekallikrein-modulating compositions and methods of use thereof
|
|
US20250327041A1
(en)
|
2022-02-24 |
2025-10-23 |
Io Biotech Aps |
Nucleotide delivery of cancer therapy
|
|
WO2023233290A1
(en)
|
2022-05-31 |
2023-12-07 |
Janssen Sciences Ireland Unlimited Company |
Rnai agents targeting pd-l1
|
|
JP2025522433A
(ja)
|
2022-06-15 |
2025-07-15 |
アローヘッド ファーマシューティカルズ インコーポレイテッド |
スーパーオキシドジスムターゼ１（ＳＯＤ１）の発現を阻害するためのＲＮＡｉ剤、その組成物、及び使用の方法
|
|
EP4684015A2
(en)
|
2023-03-21 |
2026-01-28 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of complement factor b (cfb), pharmaceutical compositions thereof, and methods of use
|
|
TW202448484A
(zh)
|
2023-04-20 |
2024-12-16 |
美商雅迪克斯製藥公司 |
Ｍａｐｔ調節組合物及其使用方法
|
|
WO2024238396A1
(en)
|
2023-05-12 |
2024-11-21 |
Adarx Pharmaceuticals, Inc. |
Nmda ligand conjugated compounds and uses thereof
|
|
CN121335980A
(zh)
|
2023-05-26 |
2026-01-13 |
阿达尔克斯制药有限公司 |
Sod1调节组合物及其使用方法
|
|
EP4731763A1
(en)
|
2023-06-20 |
2026-04-29 |
Adarx Pharmaceuticals, Inc. |
Lrrk2-modulating compositions and methods of use thereof
|
|
IL326882A
(en)
|
2023-08-30 |
2026-04-01 |
Arrowhead Pharmaceuticals Inc |
RNAi agents for inhibiting expression of inhibitory subunit beta E (INHBE), their pharmaceutical compositions and methods of use
|
|
EP4520345A1
(en)
|
2023-09-06 |
2025-03-12 |
Myneo Nv |
Product
|
|
WO2025072748A2
(en)
|
2023-09-29 |
2025-04-03 |
Insitro, Inc. |
Compositions and methods for treating nonalcoholic fatty liver disease
|
|
WO2025137384A1
(en)
|
2023-12-20 |
2025-06-26 |
Arrowhead Pharmaceuticals, Inc. |
Methods and reagents for improved oligonucleotide synthesis
|
|
US12553050B2
(en)
|
2024-03-22 |
2026-02-17 |
Takeda Pharmaceutical Company Limited |
Compositions and methods for inhibiting cytochrome P450 family 7 subfamily a member 1 (CYP7A1) expression
|
|
US12551569B2
(en)
|
2024-03-31 |
2026-02-17 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents for inhibiting expression of microtubule associated protein tau (MAPT), compositions thereof, and methods of use
|
|
WO2025226980A2
(en)
|
2024-04-25 |
2025-10-30 |
Insitro, Inc. |
Compositions and methods for treating metabolic dysfunction-associated steatotic liver disease
|
|
WO2025265013A2
(en)
|
2024-06-20 |
2025-12-26 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of huntingtin (htt), compositions thereof, and methods of use
|
|
WO2026044017A2
(en)
|
2024-08-21 |
2026-02-26 |
Insitro, Inc. |
Compositions and methods for treating nonalcoholic fatty liver disease
|